Previous Close | 69.34 |
Open | 69.35 |
Bid | 68.82 x 800 |
Ask | 68.86 x 800 |
Day's Range | 68.50 - 69.25 |
52 Week Range | 33.33 - 73.50 |
Volume | 135,032 |
Avg. Volume | 154,666 |
Market Cap | 11.475B |
Beta (5Y Monthly) | 0.00 |
PE Ratio (TTM) | 49.07 |
EPS (TTM) | 1.40 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.33 (0.48%) |
Ex-Dividend Date | Jul 10, 2020 |
1y Target Est | 69.82 |
Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced today that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that the independent Data and Safety Monitoring Board (DSMB) has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications.